文献速递前列腺癌

持续雄激素剥夺治疗中睾酮达标者随访睾酮水平波动大:对临床实践的意义

Testosterone Responders to Continuous Androgen Deprivation Therapy Show Considerable Variations in Testosterone Levels on Followup: Implications for Clinical Practice.
PubMed 文献 · J Urol · 2017-07-25

该回顾性随机样本研究纳入2007至2016年间在大学健康网络接受持续雄激素剥夺治疗、初始血清睾酮低于0.7 nmol/l的514例前列腺癌患者,中位随访20.3个月。5年内分别有82%、45%和18%的患者出现睾酮大于0.7、大于1.1和大于1.7 nmol/l的后续升高,其中96%至100%在5年内重新降至低于0.7 nmol/l。睾酮升高不是进展为去势抵抗状态的显著预测因素。

要点

  • 持续雄激素剥夺治疗中初始睾酮低于0.7 nmol/l者,5年内82%出现大于0.7 nmol/l的后续升高。
  • 5年内分别有45%和18%的患者出现睾酮大于1.1和大于1.7 nmol/l的升高。
  • 睾酮升高不是进展为去势抵抗状态的显著预测因素,不应触发医生的立即反应。

核心结论

  • 接受持续雄激素剥夺治疗且初始睾酮低于0.7 nmol/l的男性常出现后续血清睾酮升高,此类事件对肿瘤学结局无预后意义,不应触发医生的立即反应,睾酮水平最终会重新降至低于0.7 nmol/l。

研究设计与样本

  • 回顾性随机样本研究,纳入2007至2016年间在大学健康网络接受持续雄激素剥夺治疗、血清睾酮低于0.7 nmol/l的514例前列腺癌患者。
  • 从首次睾酮测量值低于0.7 nmol/l之日起随访至进展为去势抵抗、死亡或研究期结束。

主要发现

  • 患者中位年龄74岁,中位随访20.3个月。
  • 5年随访内分别有82%、45%和18%的患者出现后续睾酮大于0.7、大于1.1和大于1.7 nmol/l。
  • 这些患者中96%至100%在5年内睾酮重新降至低于0.7 nmol/l。
  • 无患者基线特征与睾酮升高相关,睾酮升高不是进展为去势抵抗状态的显著预测因素。

关键数值与推荐

  • 睾酮升高阈值定义为大于0.7、大于1.1和大于1.7 nmol/l。
  • 5年内睾酮大于0.7、大于1.1和大于1.7 nmol/l的发生率分别为82%、45%和18%。
  • 睾酮升高后5年内重新降至低于0.7 nmol/l的比例为96%至100%。

临床怎么用

  • 作者认为,持续雄激素剥夺治疗中初始睾酮低于0.7 nmol/l者出现后续睾酮升高不应触发医生的立即反应,因为这些事件对肿瘤学结局无预后意义。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We determined whether men on continuous androgen deprivation therapy who achieve testosterone less than 0.7 nmol/l demonstrate subsequent testosterone elevations during followup and whether such events predict worse oncologic outcomes. MATERIALS AND METHODS: We evaluated a random, retrospective sample of 514 patients with prostate cancer treated with continuous androgen deprivation therapy in whom serum testosterone was less than 0.7 nmol/l at University Health Network between 2007 and 2016. Patients were followed from the date of the first testosterone measurement of less than 0.7 nmol/l to progression to castrate resistance, death or study period end. Study outcomes were the development of testosterone elevations greater than 0.7, greater than 1.1 and greater than 1.7 nmol/l, and progression to a castrate resistant state. Survival curves were constructed to determine the rate of testosterone elevations. Multivariate Cox regression analysis was done to assess whether elevations predicted progression to castrate resistance. RESULTS: Median patient age was 74 years and median followup was 20.3 months. Within 5 years of followup 82%, 45% and 18% of patients had subsequent testosterone levels greater than 0.7, greater than 1.1 and greater than 1.7 nmol/l, respectively. In 96% to 100% of these patients levels less than 0.7 nmol/l were subsequently reestablished within 5 years. No patient baseline characteristic was associated with elevations and elevations were not a significant predictor of progression to a castrate resistant state. CONCLUSIONS: Men on continuous androgen deprivation therapy in whom initial testosterone is less than 0.7 nmol/l frequently show subsequent elevations in serum testosterone. Such a development should not trigger an immediate response from physicians as these events are prognostically insignificant with regard to oncologic outcomes. Levels are eventually reestablished at less than 0.7 nmol/l.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Sayyid RK, Sayyid AK, Klaassen Z, et al. Testosterone Responders to Continuous Androgen Deprivation Therapy Show Considerable Variations in Testosterone Levels on Followup: Implications for Clinical Practice. J Urol. 2017. PMID: 28751266. doi:10.1016/j.juro.2017.07.078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。